Tumor cell budding, defined as invasion by single tumor cells or small clusters of cells at the leading edge, is an independent adverse prognostic factor in CRC and predicts response to antiepidermal growth factor receptor (EGFR) therapy [8, 10]. The gene discussed is EGFR; the disease is neoplasm.